Target intelligence / Profile preview

ADP-ribosylhydrolase 1 (ARH1)

Target: ARH1
Molecular classification: Enzyme, Mono(ADP-ribosyl)hydrolase

Overview

ADP-ribosylhydrolase 1 (ARH1) is a cytoplasmic enzyme that catalyzes the removal of ADP-ribose groups from arginine residues of proteins, a process known as mono-ADP-ribosylhydrolysis[3][4]. This enzyme is essential for reversing the regulatory effects of mono-ADP-ribosylation in cellular processes. ARH1 plays a role in intracellular signal transduction and cell cycle progression, and its deficiency is linked to abnormal cell proliferation and a predisposition to several cancer types[4]. The enzyme is ubiquitously expressed in human tissues and is the main cytoplasmic hydrolase for arginine-linked ADP-ribosylation modifications[4]. Human mutations in ARH1 are associated with certain cancers, and estrogen-dependent phenotypes have been observed in ARH1-deficient models[4].

Other names: Protein ADP-ribosylarginine hydrolaseProtein-Nω-(ADP-D-ribosyl)-L-arginine ADP-ribosylhydrolaseARH1

Mechanism of action

Removal of ADP-ribose modifications from arginine residues in proteins, reversing the functional changes induced by mono-ADP-ribosylation

Biological functions

Hydrolysis of ADP-ribose-arginine bonds on proteinsReversal of mono-ADP-ribosylationIntracellular signal transductionCell cycle regulation

Disease associations

Cancer (loss of ARH1 increases risk and tumorigenesis)Other (general cell proliferation and abnormal growth)

Safety considerations

Loss of ARH1 function is associated with increased cell proliferation, shortened cell cycle, and enhanced tumorigenesisPotential for off-target effects if modulating ADP-ribosylation globally

Biomarkers

Somatic mutations in ARH1 (e.g., in lung, breast, colon cancer)

Beyond the preview

Go deeper on ADP-ribosylhydrolase 1 (ARH1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

Drug candidates
Developers
Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

Trial design
Status
Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

Programs
Modalities
Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

Publications
Sources
Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

Patents
Assignees
Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

Biology
Development news
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ADP-ribosylhydrolase 1 (ARH1).

Explore the full profile